BioSpace News Archive

Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.

Medical device maker Medtronic and Novo Nordisk have entered a collaboration pact to develop ways of integrating insulin dosing management data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring devices from Medtronic.

The miniature heart had all the structures of a full-sized heart, with four internal chambers. The company says it is as close as anyone has gotten to a fully functioning heart via 3D bioprinting.

Celgene announced topline data from its Phase III QUAZAR AML-001 trial.

Auris Medical Holding Ltd. announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen® from the U.S. Food and Drug Administration and from the European Medicines Agency.

Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.

A study carried out with a new human stem cell-derived model reveals that the most prevalent genetic risk factor of Alzheimer’s disease, apolipoprotein E4, impairs the function of human brain immune cells, microglia.

Key Opinion Leaders in the field of Proton Therapy shared their latest insights and research on FLASH1 irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on Proton Therapy

BioCardia announced that the independent Data Safety Monitoring Board has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019.

Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.